These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33471444)

  • 1. Do Drug-likeness Rules Apply to Oral Prodrugs?
    Protti ÍF; Rodrigues DR; Fonseca SK; Alves RJ; de Oliveira RB; Maltarollo VG
    ChemMedChem; 2021 May; 16(9):1446-1456. PubMed ID: 33471444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To be drug or prodrug: structure-property exploratory approach regarding oral bioavailability.
    Damião MC; Pasqualoto KF; Polli MC; Parise Filho R
    J Pharm Pharm Sci; 2014; 17(4):532-40. PubMed ID: 25579432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to improve oral drug bioavailability.
    Gomez-Orellana I
    Expert Opin Drug Deliv; 2005 May; 2(3):419-33. PubMed ID: 16296764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist.
    Beaumont K; Webster R; Gardner I; Dack K
    Curr Drug Metab; 2003 Dec; 4(6):461-85. PubMed ID: 14683475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ask the experts: past, present and future of the rule of five.
    Baell J; Congreve M; Leeson P; Abad-Zapatero C
    Future Med Chem; 2013 May; 5(7):745-52. PubMed ID: 23651089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the Physicochemical Properties of Acaricides Based on Lipinski's Rule of Five.
    Chen X; Li H; Tian L; Li Q; Luo J; Zhang Y
    J Comput Biol; 2020 Sep; 27(9):1397-1406. PubMed ID: 32031890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening.
    Zuegg J; Cooper MA
    Curr Top Med Chem; 2012; 12(14):1500-13. PubMed ID: 22827520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption matters: A closer look at popular oral bioavailability rules for drug approvals.
    Caminero Gomes Soares A; Marques Sousa GH; Calil RL; Goulart Trossini GH
    Mol Inform; 2023 Nov; 42(11):e202300115. PubMed ID: 37550251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amorphous Solid Dispersions or Prodrugs: Complementary Strategies to Increase Drug Absorption.
    Rumondor ACF; Dhareshwar SS; Kesisoglou F
    J Pharm Sci; 2016 Sep; 105(9):2498-2508. PubMed ID: 26886316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
    Müller CE
    Chem Biodivers; 2009 Nov; 6(11):2071-83. PubMed ID: 19937841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diverse approaches for the enhancement of oral drug bioavailability.
    Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
    Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted prodrug design to optimize drug delivery.
    Han HK; Amidon GL
    AAPS PharmSci; 2000; 2(1):E6. PubMed ID: 11741222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
    Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
    J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
    Gupta D; Varghese Gupta S; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
    Mol Pharm; 2013 Feb; 10(2):512-22. PubMed ID: 23244438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel strategy for ADME screening of prodrugs: combined use of serum and hepatocytes to integrate bioactivation and clearance, and predict exposure to both active and prodrug to the systemic circulation.
    Hoppe E; Hewitt NJ; Buchstaller HP; Eggenweiler HM; Sirrenberg C; Zimmermann A; März J; Schwartz H; Saal C; Meyring M; Hecht S
    J Pharm Sci; 2014 May; 103(5):1504-14. PubMed ID: 24648352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How "drug-like" are naturally occurring anti-cancer compounds?
    Ntie-Kang F; Lifongo LL; Judson PN; Sippl W; Efange SM
    J Mol Model; 2014 Jan; 20(1):2069. PubMed ID: 24452907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current prodrug design for drug discovery.
    Hsieh PW; Hung CF; Fang JY
    Curr Pharm Des; 2009; 15(19):2236-50. PubMed ID: 19601825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating physiochemical properties of FDA-approved orally administered drugs.
    Reese TC; Devineni A; Smith T; Lalami I; Ahn JM; Raj GV
    Expert Opin Drug Discov; 2024 Feb; 19(2):225-238. PubMed ID: 37921049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is prodrug design an approach to increase water solubility?
    Sanches BMA; Ferreira EI
    Int J Pharm; 2019 Sep; 568():118498. PubMed ID: 31301465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prodrug approaches for CNS delivery.
    Rautio J; Laine K; Gynther M; Savolainen J
    AAPS J; 2008; 10(1):92-102. PubMed ID: 18446509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.